Charles River Laboratories (CRL) Tops Q3 EPS by 17c, provides guidance
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $187.51 -0.29%
Revenue Growth %: -5.1%
Financial Fact:
Interest expense: -7.08M
Today's EPS Names:
PLCE, COE, JVA, More
Revenue Growth %: -5.1%
Financial Fact:
Interest expense: -7.08M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $2.59, $0.17 better than the analyst estimate of $2.42. Revenue for the quarter came in at $1.01 billion versus the consensus estimate of $976 million.
GUIDANCE:
Charles River Laboratories sees FY2024 EPS of $10.10-$10.30, versus the consensus of $10.00.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- XORTX to voluntarily delist from TSX Venture Exchange
- Lockheed Martin wins $2.8B in Defense contracts for F-35, helicopters
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
